Gui Nannan, Cheewakriangkrai Chalong, Chaiyawat Parunya, Udomruk Sasimol
Department of Obstetrics and Gynecology, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.
Department of Obstetrics and Gynecology, Faculty of Medicine, Affiliated Hospital of Youjiang Medical University for Nationalities, Baise 533000, China.
Diagnostics (Basel). 2025 Jul 30;15(15):1916. doi: 10.3390/diagnostics15151916.
Endometrial cancer is one of the most prevalent gynecologic malignancies in developed countries, with its incidence steadily increasing each year. Early diagnosis is crucial for a favorable prognosis; however, certain patients experience recurrence and distant metastasis after surgery, similar to advanced cancer patients, with limited treatment options. Therefore, effective strategies for early screening, diagnosis, predicting local recurrence, and guiding rapid treatment interventions are essential for improving survival rates and prognosis. Liquid biopsy, a method known for being non-invasive, safe, and effective, has attracted widespread attention for cancer diagnosis and treatment. Although its clinical application in endometrial cancer is less established than in other cancers, research on biomarkers using liquid biopsy in endometrial cancer patients is currently in progress. This review examines the latest advancements in non-invasive biomarkers identified through liquid biopsy and provides a comprehensive overview of their clinical applications in endometrial cancer. Additionally, it discusses the challenges and future prospects of liquid biopsy, offering valuable insights into the diagnosis and personalized treatment of endometrial cancer.
子宫内膜癌是发达国家最常见的妇科恶性肿瘤之一，其发病率逐年稳步上升。早期诊断对于良好的预后至关重要；然而，某些患者术后会出现复发和远处转移，类似于晚期癌症患者，治疗选择有限。因此，有效的早期筛查、诊断、预测局部复发和指导快速治疗干预策略对于提高生存率和改善预后至关重要。液体活检是一种以无创、安全和有效著称的方法，在癌症诊断和治疗方面引起了广泛关注。尽管其在子宫内膜癌中的临床应用不如在其他癌症中成熟，但目前正在对子宫内膜癌患者进行使用液体活检的生物标志物研究。本综述探讨了通过液体活检鉴定出的非侵入性生物标志物的最新进展，并全面概述了它们在子宫内膜癌中的临床应用。此外，还讨论了液体活检的挑战和未来前景，为子宫内膜癌的诊断和个性化治疗提供了有价值的见解。
